ESC Congress 2025 Press Activities

Press materials (slides, press releases and press conferences recordings) will be available on this page at the embargo lift.

All times indicated are CEST.

Accredited press will access embargoed materials and embargoed press conferences on the exclusive webpage.

Become accredited here.

Welcome to ESC Congress 2025

Professor Tomasz Guzik delivers an exciting preview of ESC Congress 2025, where so much is set to unfold!

Press conferences

Thursday 28 August 15:30 to 16:30 - Hot Line Press Conference 1

Chairperson: Jose Luis Merino (Madrid, Spain)

Embargo CEST	Presentation Title	Presenter
Friday 29 August 11:00	POTCAST – a Randomized Controlled Trial of Arrhythmia prevention using targeted plasma potassium levels in ICD Patients	Dr Christian Jons, (Copenhagen, Danemark)
Friday 29 August 11:15	AMALFI: Active Monitoring for Atrial Fibrillation	Dr Rohan Wijesurendra (Oxford, UK)
Friday 29 August 11:30	DIGIT-HF: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction	Prof Udo Bavendiek (Hannover, Germany)
Friday 29 August 11:45	DOUBLE-CHOICE: Anesthesia strategies and self-expanding valve types for TAVI	Prof Mohamed Abdel-Wahab (Liepzig, Germany)

Friday 29 August 12:00 to 13:00 - Guidelines Press Conference

Chairpersons: Ulf Landmesser (Germany) and Stefan James (Sweden)

Embargo CEST	Presentation Title	Presenter
Friday 29 August 08:15	Cardiovascular disease and pregnancy (Guidelines)	Julie De Backer and Kristina Hermann Haugaa
Friday 29 August 08:15	Mental health and cardiovascular disease (Consensus Statement)	Hector Bueno and Christi Deaton
Friday 29 August 08:15	Myocarditis and pericarditis (Guidelines)	Massimo Imazio and Jeanette Schulz-Menger
Friday 29 August 08:15	Valvular heart disease (Joint Guidelines with EACTS)	Fabien Praz and Michael A. Borger
Friday 29 August 08:15	Focused update of the 2019 dyslipidaemias guidelines	François Mach, Konstantinos Koskinas and Jeanine Roeters Van Lennep

Friday 29 August 13:30 to 14:30 - Hot Line Press Conference 2 and 3

Chairperson: Filippo Crea (Roma, Italy)

Embargo CEST	Presentation Title	Presenter
Saturday 30 August 08:15	DAPA ACT HF-TIMI 68: Dapagliflozin in Patients Hospitalized for Acute Heart Failure	Dr David Berg (Boston, USA)
Saturday 30 August 08:33	VICTOR: Vericiguat Global Study in Participants with Chronic Heart Failure	Prof Faiez Zannad (Paris, France)
Saturday 30 August 09:08	ODYSSEY-HCM: Mavacamten in nHCM	Dr Milind Desai (Cleveland, USA)
Saturday 30 August 09:18	MAPLE-HCM: aficamten vs metoprolol in oHCM	Dr Pablo Garcia-Pavia (Madrid, Spain)
Saturday 30 August 11:00	REBOOT-CNIC: betablockers after infarction with LVEF greater than 40%	Prof Ibanez Borja (Madrid, Spain)
Saturday 30 August 11:15	THE BETAMI-DANBLOCK Trial: randomized discontinuation of beta-blockers after myocardial infarction	Prof Dan Atar (Oslo, Norway)/ Prof Eva Prescott (Copenhagen, Danemark)

Friday 29 August 15:30 to 16:30 - Hot Line Press Conference 4 and 5

Chairperson: Isabel Goncalves (Malmo, Sweden)

Embargo CEST	Presentation Title	Presenter
Saturday 30 August 16:15	BaxHTN – Efficacy and safety of the aldosterone synthase inhibitor baxdrostat in patients with uncontrolled or resistant hypertension	Prof Bryan Williams (London, UK)
Saturday 30 August 16:30	KARDIA-3: Zilebesiran as Add-on Therapy in Adults with Hypertension and Established Cardiovascular Disease or at High Cardiovascular Risk	Dr Neha Pagidipati (Durham, USA)
Saturday 30 August 16:45	Essence-TIMI 73b	Dr Brian Bergmark (Boston, USA)
Saturday 30 August 17:30	DANCAVAS 2: Screening and intervention to prevent cardiovascular disease and death	Prof Axel Diederichsen (Odense C, Danemark)
Saturday 30 August 18:00	ABC-AF study - a randomised controlled study of personalised treatment to reduce stroke or death in atrial fibrillation	Prof Jonas Oldgren (Uppsala, Sweden)

Saturday 30 August 12:30 to 13:30 - Hot Line Press Conference 6

Chairperson: Dan Atar (Oslo, Norway)

Embargo CEST	Presentation Title	Patient representative
Sunday 31 August 08:15	SWEDEPAD 1 and 2: Impact of drug-coated devices in patients with peripheral arterial disease	Prof Marten Falkenberg (Gothenburg, Sweden)
Sunday 31 August 08:51	The AQUATIC trial	Prof Martine Gilard (Brest, France)
Sunday 31 August 09:09	The DUAL-ACS Trial: Duration of DAPT in ACS	Prof David Newby (Edinburgh, UK)

Embargo CEST

Presentation Title

Patient representative

Sunday 31 August

08:15

SWEDEPAD 1 and 2: Impact of drug-coated devices in patients with peripheral arterial disease

Prof Marten Falkenberg (Gothenburg, Sweden)

Sunday 31 August

08:51

The AQUATIC trial

Prof Martine Gilard (Brest, France)

Sunday 31 August

09:09

The DUAL-ACS Trial: Duration of DAPT in ACS

Prof David Newby (Edinburgh, UK)

Saturday 30 August 15:00 to 16:00 - Hot Line Press Conference 7 et 8

Chairperson: Carlos Aguiar (Lisbon, Portugal)

Embargo CEST	Presentation Title	Presenter
Sunday 31 August 16:15	NEO-MINDSET: Early withdrawal of aspirin after percutaneous coronary intervention for acute coronary syndrome	Prof Pedro Lemos (Sao Paulo, Brazil)
Sunday 31 August 16:30	TAILORED-CHIP: Tailored Antiplatelet Therapy for Complex High-Risk PCI	Prof Duk-Woo Park (Seoul, Korea)
Sunday 31 August 17:00	DAPT-SHOCK-AMI trial, Cangrelor in cardiogenic shock.	Prof Zuzana Motovska (Prague, Czechia)
Sunday 31 August 17:30	ALONE-AF: Discontinuing long-Term oral anticoagulation after successful atrial fibrillation ablation	Prof Boyoung Joung (Seoul, Korea)
Sunday 31 August 17:47	BEAT PAROX AF: a randomized comparison of PFA vs RFA	Prof Pierre Jais (Bordeaux, France)

Sunday 31 August 15:00 to 16:00 - Hot Line Press Conference 9 and 10

Chairperson: Dan Atar (Olso, Norway)

Embargo CEST	Presentation Title	Presenter
Monday 1 September 8:15	PARACHUTE-HF: Randomized trial comparing sacubitril/valsartan with enalapril in patients with HFrEF caused by chronic Chagas cardiomyopathy	Prof Renato Lopes (Durham, USA)
Monday 1 September 8:37	HELP-MI SWEDEHEART – Randomised H. pylori screening after MI	Prof Robin Hofmann (Stockholm, Sweden)
Monday 1 September 13:45	NEWTON-CABG CardioLink-5: Evolocumab and Saphenous Vein Graft Patency	Prof Subodh Verma (Toronto, Canada)
Monday 1 September 14:03	TACSI: Dual or single antiplatelet therapy after CABG in patients with acute coronary syndrome	Prof Anders Jeppsson (Gothenburg, Sweden)

New 2025 ESC Guidelines

Publication Friday 29 August at 8:15 CEST

Cardiovascular disease and pregnancy (Guidelines)
Chairpersons: Julie De Backer and Kristina Hermann Haugaa

Mental health and cardiovascular disease (Consensus Statement)
Chairpersons: Hector Bueno and Christi Deaton

Myocarditis and pericarditis (Guidelines)
Chairpersons: Massimo Imazio and Jeanette Schulz-Menger

Valvular heart disease (Joint Guidelines with EACTS)
Chairpersons: Fabien Praz and Michael A. Borger

Focused update of the 2019 dyslipidaemias guidelines
Chairpersons: François Mach, Konstantinos Koskinas and Jeanine Roeters Van Lennep

ESC Congress 2025 Press Releases

Date

Title

Topic(s)

Date: 01 Sep 2025

Title: Evolocumab did not improve vein graft disease following coronary artery bypass surgery

Topic(s): Coronary Artery Disease (Chronic); Cardiovascular Pharmacotherapy
Date: 01 Sep 2025

Title: Reconditioned pacemakers provide new hope for patients in low- and middle-income countries

Topic(s): Interventional Cardiology
Date: 01 Sep 2025

Title: Routine Helicobacter pylori screening does not significantly reduce upper gastrointestinal bleeding in patients after a heart attack

Topic(s): Risk Factors and Prevention
Date: 01 Sep 2025

Title: Lack of benefit from left atrial appendage occlusion for some patients after valvular surgery

Topic(s): Cardiovascular Surgery
Date: 01 Sep 2025

Title: Home-based hypertension care is effective in rural South Africa

Topic(s): Hypertension
Date: 01 Sep 2025

Title: Dual antiplatelet therapy is not more effective than aspirin alone after coronary artery bypass grafting

Topic(s): Coronary Artery Disease (Chronic); Cardiovascular Pharmacotherapy
Date: 01 Sep 2025

Title: Positive results revealed from the first prospective trial in heart failure due to Chagas disease

Topic(s): Heart Failure
Date: 01 Sep 2025

Title: De-escalation of dual antiplatelet therapy provides benefits in patients after coronary artery bypass grafting

Topic(s): Coronary Artery Disease (Chronic); Cardiovascular Pharmacotherapy
Date: 31 Aug 2025

Title: Intravenous blood thinner investigated in cardiogenic shock caused by acute myocardial infarction

Topic(s): Cardiovascular Pharmacotherapy
Date: 31 Aug 2025

Title: Drug-coated devices do not improve outcomes in patients with peripheral artery disease

Topic(s): Interventional Cardiology
Date: 31 Aug 2025

Title: Early aspirin discontinuation linked to benefits in low-risk patients with myocardial infarction undergoing coronary stenting

Topic(s): Cardiovascular Pharmacotherapy
Date: 31 Aug 2025

Title: Early escalation and late de-escalation of antiplatelet therapy is not beneficial in patients after complex stenting

Topic(s): Cardiovascular Pharmacotherapy
Date: 31 Aug 2025

Title: Routine heart CT scanning is not warranted after stenting for left main coronary artery disease

Topic(s): Coronary Artery Disease (Chronic)
Date: 31 Aug 2025

Title: Digital twin technology helps reduce the recurrence of atrial arrhythmias after catheter ablation for persistent atrial fibrillation

Topic(s): Atrial Fibrillation
Date: 31 Aug 2025

Title: Pulsed field ablation was not superior to radiofrequency ablation in paroxysmal atrial fibrillation

Topic(s): Atrial Fibrillation
Date: 31 Aug 2025

Title: New trial evidence on the use of blood thinners after coronary stenting

Topic(s): Cardiovascular Pharmacotherapy
Date: 31 Aug 2025

Title: Worse outcomes with aspirin in high-risk chronic coronary syndrome patients who require long-term anticoagulation

Topic(s): Coronary Artery Disease (Chronic); Pharmacology and Pharmacotherapy
Date: 31 Aug 2025

Title: Trial findings support 3 months of blood thinners, rather than 12 months, in patients after a heart attack

Topic(s): Cardiovascular Pharmacotherapy
Date: 31 Aug 2025

Title: New data presented to guide the treatment of patients with multivessel coronary artery disease

Topic(s): Coronary Artery Disease (Chronic)
Date: 31 Aug 2025

Title: New data on oral anticoagulation after successful ablation of atrial fibrillation

Topic(s): Atrial Fibrillation
Date: 30 Aug 2025

Title: Evidence appears supportive for the initiation of SGLT2 inhibitors in patients hospitalised for heart failure

Topic(s): Heart Failure
Date: 30 Aug 2025

Title: No benefit seen when biomarker-based risk scores are used to personalise atrial fibrillation treatment

Topic(s): Atrial Fibrillation
Date: 30 Aug 2025

Title: Aficamten is superior to metoprolol for symptomatic obstructive hypertrophic cardiomyopathy

Topic(s): Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
Date: 30 Aug 2025

Title: Olezarsen reduces levels of the blood fat, triglycerides, in patients at high cardiovascular risk

Topic(s): Risk Factors and Prevention
Date: 30 Aug 2025

Title: No significant reduction in death following an invitation to undergo comprehensive cardiovascular screening in men aged 60 to 64 years

Topic(s): Risk Factors and Prevention
Date: 30 Aug 2025

Title: Beta-blockers did not reduce cardiovascular events in selected heart attack patients in the REBOOT trial

Topic(s): Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
Date: 30 Aug 2025

Title: Beta-blockers reduced cardiovascular events in selected heart attack patients without heart failure in the BETAMI-DANBLOCK trials

Topic(s): Acute Coronary Syndromes
Date: 30 Aug 2025

Title: Meta-analysis finds that beta-blockers improve outcomes after a heart attack in patients with mildly reduced heart function

Topic(s): Acute Cardiac Care; Acute Coronary Syndromes
Date: 30 Aug 2025

Title: No improvements with mavacamten in symptomatic nonobstructive hypertrophic cardiomyopathy

Topic(s): Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
Date: 30 Aug 2025

Title: Vericiguat did not meet its primary endpoint but lowered the risk of cardiovascular death in patients with heart failure

Topic(s): Chronic Heart Failure
Date: 30 Aug 2025

Title: Blood-pressure reductions with baxdrostat in patients with uncontrolled or resistant hypertension

Topic(s): Hypertension
Date: 30 Aug 2025

Title: Ivabradine did not reduce the occurrence of myocardial injury after noncardiac surgery

Topic(s): Cardiovascular Surgery
Date: 30 Aug 2025

Title: KARDIA-3 trial examines blood-pressure lowering effects of zilebesiran in hypertensive patients at high cardiovascular risk

Topic(s): Hypertension
Date: 30 Aug 2025

Title: Pooled analysis supports the benefits of vericiguat across a broad range of heart failure patients

Topic(s): Chronic Heart Failure
Date: 30 Aug 2025

Title: Implantable cardioverter defibrillators did not improve mortality in selected heart-attack patients with abnormal heart rhythm markers

Topic(s): Interventional Cardiology
Date: 30 Aug 2025

Title: Extended blood-thinning treatment lowers recurrence in at-risk patients with provoked venous thromboembolism

Topic(s): Cardiovascular Pharmacotherapy
Date: 30 Aug 2025

Title: Early and sustained LDL-C goal achievement with inclisiran in patients at high cardiovascular risk

Topic(s): Risk Factors and Prevention
Date: 29 Aug 2025

Title: ESC calls for a cultural shift to deal with the adverse combination of mental health conditions and cardiovascular disease

Topic(s): Cardiovascular Risk Assessment; Stress, Psycho-Social and Cultural Aspects of Heart Disease; Risk Factors and Prevention; Depression and Heart Disease
Date: 29 Aug 2025

Title: New ESC/EACTS Guidelines Guidelines for Valvular Heart Disease will help prevent under treatment of patients and support more equitable, higher quality care

Topic(s): Diseases of the Aorta, Peripheral Vascular Disease, Stroke
Date: 29 Aug 2025

Title: New guidance recommends a new approach to assess cardiovascular risk and reach treatment goals for lipid levels

Topic(s): Preventive Cardiology
Date: 29 Aug 2025

Title: Digitoxin improves outcomes in advanced heart failure

Topic(s): Heart Failure
Date: 29 Aug 2025

Title: Remote atrial fibrillation screening using an ECG patch demonstrates modest benefits

Topic(s): Atrial Fibrillation
Date: 29 Aug 2025

Title: Increasing potassium levels improve outcomes in patients at high risk of ventricular arrhythmia

Topic(s): Arrhythmias, General; Risk Factors and Prevention
Date: 29 Aug 2025

Title: New data support a minimalist approach for transcatheter aortic valve implantation

Topic(s): Interventional Cardiology
Date: 29 Aug 2025

Title: New Guidelines for myocarditis and pericarditis aim to improve diagnosis and treatment – and help patients return to exercise and work more quickly

Topic(s): Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
Date: 29 Aug 2025

Title: Updated ESC Guidelines put focus on women’s autonomy to make their own reproductive choices about high-risk pregnancies

Topic(s): Cardiovascular Disease in Women
Date: 28 Aug 2025

Title: New systematic review and meta-analysis shows an association between shingles vaccination and lower risk of heart attack and stroke 

Topic(s): Risk Factors and Prevention
Date: 28 Aug 2025

Title: Predictable structures in music synchronises blood pressure the most, and could be used to create personalised music-based cardiovascular therapies 

Topic(s): Risk Factors and Prevention
Date: 27 Aug 2025

Title: Older age and low fitness levels are associated with heartbeat abnormalities that increase future cardiovascular risk

Topic(s): Risk Factors and Prevention; Physical Inactivity and Exercise
Date: 27 Aug 2025

Title: Treating heart failure patients with anti-obesity medication reduces greenhouse gas emissions and improves clinical outcomes

Topic(s): Chronic Heart Failure
Date: 27 Aug 2025

Title: Cardiac arrest in space: New research shows that automatic chest compressions are more effective for CPR when both rescuer and patient are floating in microgravity

Topic(s): Environmental and Occupational Aspects of Heart Disease; Cardiovascular Disease in Special Populations

: See what's on the programme

It’s all here. The very latest science on all cardiovascular topics.

With live and on-demand content, you can create your ESC Congress your way. Fill your agenda with the presentations you don’t want to miss.